Aarkstore - Paroxysmal Nocturnal Hemoglobinuria-Pipeline Insights, 2014

1
Paroxysmal Nocturnal Hemoglobinuria-Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/healthcare/77316/-paroxys
  mal-nocturnal-hemoglobinuria-pipeline-insights-201
  4

2
Summary

• DelveInsights, Paroxysmal Nocturnal
  Hemoglobinuria-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this indication. A key objective of
  the report is to establish the understanding for
  all the pipeline drugs that fall under Paroxysmal
  Nocturnal Hemoglobinuria. This report provides
  information on the therapeutic development based
  on the Paroxysmal Nocturnal Hemoglobinuria
  dealing with all the pipeline drugs, comparative
  analysis at various stages covering Filed, Phase
  III, Phase II, Phase I, IND filed, Preclinical,
  Discovery and unknown stages, therapeutics
  assessment by monotherapy and combination
  products and molecule type drug information. The
  report also covers the companies information
  involved in the therapeutic development of the
  products. It also has highlighted the
  discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Note This report requires
  certain updates. We have all the information
  available but require 3 business days to complete
  the process and ensure it is as up-to-date as
  possible. Certain sections in the report may be
  removed or altered based on the availability and
  relevance of data for the indicated Indication.

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Paroxysmal Nocturnal
  HemoglobinuriaThe report provides pipeline
  products under drug profile section which
  includes product description, MOA, licensors
  collaborators, development partner and chemical
  informationCoverage of the Paroxysmal Nocturnal
  Hemoglobinuria pipeline on the basis of target,
  MOA, route of administration, technology involved
  and molecule typeThe report reviews key players
  involved in the therapeutics development for
  Paroxysmal Nocturnal Hemoglobinuria and also
  provide company profilingThe report also gives
  the information of dormant and discontinued
  pipeline projects Pipeline products coverage
  based on various stages of development ranging
  from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete Pipeline intelligence
  and complete understanding over therapeutics
  development for Paroxysmal Nocturnal
  HemoglobinuriaIdentify the relationship between
  the drugs and use it for target finding, drug
  repurposing, and precision medicine.Devise
  corrective measures for pipeline projects by
  understanding Paroxysmal Nocturnal Hemoglobinuria
  pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based
  DecisionsYou can order full Report with TOC and
  for Sample page visit _at_http//www.aarkstore.com/h
  ealthcare/77316/-paroxysmal-nocturnal-hemoglobinur
  ia-pipeline-insights-2014

7
Table of Content

• Paroxysmal Nocturnal Hemoglobinuria
  OverviewParoxysmal Nocturnal Hemoglobinuria
  Pipeline TherapeuticsParoxysmal Nocturnal
  Hemoglobinuria Therapeutics under Development by
  Companies Paroxysmal Nocturnal Hemoglobinuria
  Late Stage Products (Filed and Phase
  III)Comparative Analysis Paroxysmal Nocturnal
  Hemoglobinuria Mid Clinical Stage Products (Phase
  II)Comparative Analysis Paroxysmal Nocturnal
  Hemoglobinuria Early Clinical Stage Products
  (Phase I and IND Filed)Comparative
  Analysis Paroxysmal Nocturnal Hemoglobinuria
  Discovery and Pre-Clinical Stage
  Products Comparative Analysis Drug Candidate
  Profiles

8
Table of Content

• Paroxysmal Nocturnal Hemoglobinuria Therapeutics
  Assessment Assessment by Monotherapy
  Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Paroxysmal Nocturnal Hemoglobinuria
  Discontinued Products Paroxysmal Nocturnal
  Hemoglobinuria Dormant ProductsCompanies
  Involved in Therapeutics Development for
  Paroxysmal Nocturnal Hemoglobinuria Appendix Met
  hodology Contact Us Disclaimer

9
List of Tables

• Number of Products under Development for
  Paroxysmal Nocturnal Hemoglobinuria, 2014Number
  of Products under Development by
  Companies Comparative Analysis by Late Clinical
  Stage Products (Filed and Phase III),
  2014Comparative Analysis Mid Clinical Stage
  Products (Phase II), 2014Comparative Analysis
  Early Clinical Stage Products (Phase I and IND
  Filed), 2014Comparative Analysis Discovery and
  Pre-Clinical Stage Products, 2014Drug Candidates
  ProfilesParoxysmal Nocturnal Hemoglobinuria
  Assessment by Monotherapy Products Paroxysmal
  Nocturnal Hemoglobinuria Assessment by
  Combination Products Paroxysmal Nocturnal
  Hemoglobinuria Assessment by Route of
  Administration

10
List of Tables

• Paroxysmal Nocturnal Hemoglobinuria Assessment by
  Stage and Route of Administration Paroxysmal
  Nocturnal Hemoglobinuria Assessment by Molecule
  Type Paroxysmal Nocturnal Hemoglobinuria
  Assessment by Stage and Molecule Type Paroxysmal
  Nocturnal Hemoglobinuria Therapeutics
  Discontinued Products Paroxysmal Nocturnal
  Hemoglobinuria Therapeutics Dormant
  ProductsProducts under Development by Companies,
  2014

11
List of Figures

• Number of Products under Development for
  Paroxysmal Nocturnal Hemoglobinuria, 2014Late
  Clinical Stage Products (Filed and Phase III),
  2014Mid Clinical Stage Products (Phase II),
  2014Early Clinical Stage Products (Phase I and
  IND Filed), 2014Discovery and Pre-Clinical Stage
  Products, 2014Paroxysmal Nocturnal
  Hemoglobinuria Assessment by Monotherapy
  Products Paroxysmal Nocturnal Hemoglobinuria
  Assessment by Combination Products Paroxysmal
  Nocturnal Hemoglobinuria Assessment by Route of
  Administration Paroxysmal Nocturnal
  Hemoglobinuria Assessment by Stage and Route of
  Administration Paroxysmal Nocturnal
  Hemoglobinuria Assessment by Molecule
  Type Paroxysmal Nocturnal Hemoglobinuria
  Assessment by Stage and Molecule Type

12
Related Reports

• 2015 Worldwide Medical Laboratories
  Industry-Industry Market Report
• 2015 Worldwide Pharmaceutical Preparation Mfg.
  Industry-Industry Market Report
• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Paroxysmal Nocturnal Hemoglobinuria-Pipeline
  Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights, Paroxysmal Nocturnal
  Hemoglobinuria-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this indication.
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news